Zurcher Kantonalbank (Zurich Cantonalbank) Rigel Pharmaceuticals Inc Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$2.22 - $3.45 $35,007 - $54,403	-15,769 Reduced 37.14%	26,693 $80,000
Q4 2021 Feb 01, 2022	SELL	$2.36 - $3.57 $3,750 - $5,672	-1,589 Reduced 3.61%	42,462 $113,000
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $1,788 - $2,299	511 Added 1.17%	44,051 $160,000
Q2 2021 Jul 30, 2021	BUY	$3.09 - $4.54 $25,526 - $37,504	8,261 Added 23.42%	43,540 $189,000
Q1 2021 May 03, 2021	SELL	$3.35 - $4.93 $54,501 - $80,206	-16,269 Reduced 31.56%	35,279 $121,000
Q4 2020 Jan 28, 2021	BUY	$2.35 - $3.74 $98,159 - $156,219	41,770 Added 427.18%	51,548 $180,000
Q1 2019 Apr 29, 2019	SELL	$2.0 - $2.65 $17,834 - $23,630	-8,917 Reduced 47.7%	9,778 $25,000
Q3 2018 Nov 09, 2018	BUY	$2.6 - $3.59 $15,709 - $21,690	6,042 Added 47.75%	18,695 $60,000
Q2 2018 Aug 06, 2018	BUY	$2.83 - $4.11 $35,807 - $52,003	12,653 New	12,653 $36,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account